

**Advanced stage *EGFR*-mutant NSCLC
patients with *EGFR*-TKI naive tissue
profiled by MSK-IMPACT (n = 207)**



**Patients with sensitizing
EGFR-mutations (n = 175)**



**Patients treated with
1st/2nd gen TKI (n = 153)**